Immunotherapy: a new treatment paradigm in bladder cancer. – UroToday
|
Immunotherapy: a new treatment paradigm in bladder cancer.
UroToday T-cell checkpoint blockade has become a dynamic immunotherapy for bladder cancer. In 2016, atezolizumab, an immune checkpoint inhibitor, became the first new drug approved in metastatic urothelial carcinoma (mUC) in over 30 years. In 2017, nivolumab … |
